Jinwon Life Sciences Files Patent for Improved DNA Vaccine Intradermal Injector 'Gene-Derm'

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 27th that it has jointly filed an improvement patent for the suction module of the innovative suction-type intradermal injector Gene-Derm, which is used for administering the COVID-19 vaccine (GLS-5310), with medical device developer Cubist.

The company stated, "The title of the invention is 'Suction Flat Module Preventing Contamination by Foreign Substances and Secretions,'" adding, "It prevents contamination of the suction part caused by long-term or continuous use of Gene-Derm, a medical device for DNA vaccine administration, and facilitates disinfection and maintenance."

It also explained that a comparison was made between Gene-Derm administration used in the GLS-5310 clinical study and the high-speed jet injection of ZyCoV-D, a COVID-19 DNA vaccine recently granted emergency use authorization in India, in experimental animals, confirming that equivalent or superior immunogenicity was induced.

Park Young-geun, CEO of GeneOne Life Science, said, "With this patent application, we have established a technological foundation for the rapid and safe mass vaccination of not only GLS-5310 but also DNA vaccines for emerging infectious diseases," and added, "We will strive to complete rapid prototype production and clinical evaluation so that it can be applied to the Phase 3 clinical trial and commercialization of GLS-5310."

This content was produced with the assistance of AI translation services.